Skip to content

Neuropace, Inc. NPCE Accrued Contingent Liabilities

Accrued Contingent Liabilities at other companies

Medtronic logo
MedtronicMDT
LivaNova logo
LivaNovaLIVN

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s accrued contingent liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s accrued contingent liabilities?
Neuropace, Inc. (NPCE) reported accrued contingent liabilities of $0 in Q1 2026.
What does accrued contingent liabilities mean?
These are liabilities where the timing or amount is uncertain, but the occurrence is considered probable and estimable. They typically relate to legal proceedings, warranties, or other potential claims against the company. Tracking these is vital for understanding the company's risk profile and potential impact on future financial stability.